CoChat

Use of incretin agents and risk of pancreatic cancer: a population‐based cohort study

Open access
Knapen, L. M., van Dalem, J., Keulemans, Y. C., van Erp, N. P., Bazelier, M. T., De Bruin, M. L., Leufkens, H. G. M., Croes, S., Neef, C., de Vries, F., Driessen, J. H. M. · 2016 · Diabetes, Obesity and Metabolism
Cited by 43

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Aim: To investigate the association between the use of incretin agents and the risk of pancreatic cancer. Methods: A retrospective population‐based cohort study, using data from the C linical P ractice R esearch D atalink, 2007–2012, was conducted. Patients (n = 182 428) with at least one non‐insulin antidiabetic drug ( NIAD ) prescription and aged ≥18 years during data collection, were matched one‐to‐one to control patients without diabetes. Multivariable C ox proportional hazards models and a new user design were used to estimate the hazard ratio ( HR ) of pancreatic cancer in incretin users (n = 28 370) compared with control subjects without diabetes and other NIAD ‐treated patients. Time‐dependent adjustments were made for age, sex, lifestyle, comorbidities and drug use. Results: The mean duration of follow‐up was 4.1 years for incretin users. Current NIAD use was associated with a fourfold increased risk of pancreatic cancer [ HR 4.28, 95% confidence interval ( CI ) 3.49–5.24]. This risk was almost doubled among current incretin users as compared with control subjects. Incretin use was not associated with pancreatic cancer when compared with control subjects with diabetes ( HR 1.36, 95% CI 0.94–1.96); however, the ‘new user’ design did show an association between incretin use and pancreatic cancer when compared with control subjects with diabetes. In both cohorts with prevalent and incident users of antidiabetic drugs, the risk of pancreatic cancer almost doubled in those who had recently initiated incretin therapy (up to seven prescriptions), whereas this elevated risk dropped to baseline levels with prolonged use. Conclusions: We found that incretin use was not associated with pancreatic cancer after adjustment for the severity of the underlying Type 2 Diabetes Mellitus (T2DM). The elevated risk of pancreatic cancer in those recently initiating incretin agents is likely to be caused by protopathic bias or other types of unknown distortion. The presence of considerable confounding by disease severity and the lack of a duration‐of‐use relationship do not support a causal explanation for the association between incretin agents and pancreatic cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12605

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 43

Metadata

Authors
Knapen, L. M., van Dalem, J., Keulemans, Y. C., van Erp, N. P., Bazelier, M. T., De Bruin, M. L., Leufkens, H. G. M., Croes, S., Neef, C., de Vries, F., & Driessen, J. H. M.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2016-01-08
Volume
18
Issue
3
Pages
258-265
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2132078039
Cited by
43
References
15
FWCI
2.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.